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Abstract
Background: Drug-Induced Hypersensitivity Syndrome (DIHS) is a severe and rare systemic reaction triggered by a 
drug (usually an antiepileptic drug).  We present a case of DISH and we review studies on the clinical features and 
treatment of DIHS, and on its pathogenesis in which two elements (Herpesvirus infection and the drug) interact with 
the immune system to trigger such a syndrome that can lead to death in about 20% of cases.
Case presentation: We report the case of a 26-year old woman with fever, systemic maculopapular rash, 
lymphadenopathy, hepatitis and eosinophilic leukocytosis. She had been treated with antibiotics that gave no benefit. 
She was taking escitalopram and lamotrigine for a bipolar disease 30 days before fever onset. Because the patient's 
general condition deteriorated, betamethasone and acyclovir were started. This treatment resulted in a mild 
improvement of symptoms. Steroids were rapidly tapered and this was followed with a relapse of fever and a 
worsening of laboratory parameters. Human herpesvirus 6 (HHV-6) DNA was positive as shown by PCR. Drug-Induced 
Hypersensitivity Syndrome (DIHS) was diagnosed. Symptoms regressed on prednisone (at a dose of 50 mg/die) that 
was tapered very slowly. The patient recovered completely.
Conclusions: The search for rare causes of fever led to complete resolution of a very difficult case. As DIHS is a rare 
disease the most relevant issue is to suspect and include it in differential diagnosis of fevers of unknown origin. Once 
diagnosed, the therapy is easy (steroidal administration) and often successful. However our case strongly confirms that 
attention should be paid on the steroidal tapering that should be very slow to avoid a relapse.
Background
Drug-Induced Hypersensitivity Syndrome (DIHS) is a
life-threatening systemic reaction characterized by rash,
fever, hepatitis, lymphadenopathy and leukocytosis with
eosinophilia. It is triggered by a drug (usually an antiepi-
leptic drug) started 3 weeks-3 months before symptoms
onset [1]. Several drugs have been associated with DIHS,
namely, carbamazepine, phenytoin, phenobarbital, lam-
otrigine, zonisamide, allopurinole, dapsone, minocycline,
salazosulphapyridine. Abacavir and nevirapine have been
associated with a DIHS caracterized by some peculiar
symptoms [1].
It is a rare event: the incidence ranges from 1.2 to 6 per
million person-years. Between 1:1000 to 1:10000 patients
treated with phenytoin develop DIHS.
It is even rarer in lamotrigine-treated patients in the
setting of mood disorders [2]. Adults are more likely to be
affected than children, while there is no sex predilection
[1].
Treatment with corticosteroids is often successful.
However DIHS leads to death in about 20% of cases.
We report the case of a 26-year old woman with fever,
maculopapular rash, lymphadenopathy, hepatitis and
eosinophilic leukocytosis. She had started an antiepilep-
tic drug (lamotrigine) for a bipolar disease 30 days before
fever onset. Moreover we review studies on diagnosis and
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Page 2 of 5treatment of DIHS, and on its pathogenesis in which two
elements (herpesvirus infection and the drug) interact
with the immune system to trigger the syndrome.
Case presentation
A 26-year-old woman was admitted to hospital because
of fever. She was diagnosed with von Willembrandt dis-
ease in childhood and had undergone additive masto-
plasty in 2000. She was diagnosed with bipolar disease
when she was 16 years old and had been taking escitalo-
pram and lamotrigine 30 days before fever onset. This
treatment was stopped after 4 days of fever. Twelve days
before hospital admission she presented fever (maximum:
39.5°C), asthenia, nausea, myalgia and arthralgia, and was
treated with cefixime 400 mg bid. After the third dose, a
systemic and itchy rash appeared. She was then treated
with betametason 1 mg and fenoxifenadine 120 mg for
one day, 11 days before hospital admission. Fever and
other symptoms persisted despite antibiotic and corticos-
teroid treatment. She was then treated with azithromycin
500 mg qd for 3 days.
Upon hospital admission, she complained of the above-
indicated symptoms. Medical examination showed a
maculopapular rash on the face, neck, trunk, and supe-
rior and inferior limbs; hard, tender lymph nodes mea-
suring 2-3 cm in diameter bilaterally at retronucal,
laterocervical, inguinal and axillary sites; hepatomegaly.
Laboratory results showed eosinophilic leukocytosis
(31,770/mmc; 18% eosinophils); increase of both CD4
and CD8 T lymphocytes (CD4 = 3,674/mmc and CD8 =
5,759/mmc); high aminotransferase levels (alanine amin-
otransferase [ALT] and aspartate aminotransferase [AST]
were 19-fold and 14-fold normal values, respectively),
high bilirubin level (2.84 mg/dL); and low prothrombin
activity (39%). Markers for Hepatitis A virus, Hepatitis B
virus, Hepatitis C virus were negative. Immunoglobulin-
M against herpesvirus I and II, Epstein Barr virus (EBV),
Cytomegalovirus (CMV), Rubella, Adenovirus, Coxsacki-
evirus, Influenza virus A/B, parainfluenza virus, antibod-
ies against Borrelia burgdoferi, Rickettsia conori,
Rickettsia typhi, Chlamydia trachomatis, Leishmania
infantum were negative as was Vidal-Wright serodiagno-
sis. Culture of blood, pharynx, urine, feces, and parasito-
logical examination of feces showed no infection.
Antinuclear antibodies and thyroid hormones were nor-
mal. Pathological examination of right axillary lymph
nodes showed no malignancy. The numbers of mature T
cells and dendritic cells (positive for S-100 protein and
CD 68) were increased; conversely B-cell-dependent
areas (positive for CD 20) were scarce and confined to the
cortex, and there were some eosinophils. Notably, there
were foam and hydropic cells, as is seen in lymphadenop-
athy induced by such inertial material as silicon. Bone
marrow examination was unremarkable, and culture of
bone marrow blood was negative. A computerized scan
showed hepatomegaly and no other pathological sign.
At day 2 post admission in hospital, because the
patient's general condition deteriorated, betamethasone 8
mg i.v. and acyclovir 250 mg i.v. every 8 hours for 8 days
were started as empirical treatment together with infu-
sions of fresh frozen plasma, physiological solutions, and
proton pomp inhibitors. This treatment resulted in a mild
improvement of symptoms. After 5 days of treatment, we
tapered steroids from 8 mg to 3 mg i.v. in one week. This
was associated with a relapse of fever and an increase of
aminotransferase levels and eosinophils.
Differential diagnosis involved lymphoproliferative dis-
eases, autoimmune diseases/vasculitis, infectious dis-
eases and allergic reactions to drug.
At day 11 post admission in hospital, we performed
anti-human herpesvirus 6 IgG and IgM that tested posi-
tive and Human herpesvirus 6 (HHV-6) DNA (real time
PCR) in blood that tested positive (8590 cp/mL). We sus-
pected a single disease that included all these diseases,
namely Drug-Induced Hypersensitivity Syndrome
(DIHS), also called drug reaction with eosinophilia and
systemic symptoms (DRESS) syndrome, anticonvulsant
hypersensitivity syndrome (AHS), or drug induced
pseudolymphoma. Based on diagnostic criteria (see
below), we made a diagnosis of DIHS and prescribed
prednisone 50 mg/die. Fourteen days after admission to
hospital, the fever had regressed and there was an
improvement of clinical and laboratory parameters. Ste-
roidal tapering was very slow (5% each 2 weeks). HHV-6
viremia became negative after 50 days of prednisone
treatment. At present, 18 months after hospitalization, all
parameters are normal and the patient's general condi-
tion is good.
Pathogenesis
Necessary elements for DIHS are: (1) the drug; (2) the
virus; and (3) their interplay with the immune system.
The drugs associated with DIHS include several anti-epi-
leptic drugs (see above). However, cross-sensitivity
between antiepileptic and tricyclic antidepressant agents
[3] or among different aromatic anticonvulsants [4] have
been reported in the setting of DIHS. A genetic predispo-
sition has been correlated to DIHS. Aromatic anticonvul-
sants (phenytoin, phenobarbital and carbamazepine) are
metabolized partially by the cytochrome P-450 system to
reactive aromatic epoxide. Patients with DIHS have a
defect of this detoxification system, which suggests that a
reactive metabolite or a high level of the drugs play a role
in triggering the immune response [5,6]. Relatives of
DIHS patients have this detoxification defect, and may
therefore be at an increased risk for DIHS. The abnormal
detoxification of phenytoin is thought to be inherited in
autosomic co-dominant fashion [7].
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The syndrome has also been associated with reactivation
of other members of the herpesvirus family [9], Human
herpesvirus 7 (HHV-7) [8], EBV [10] and CMV [11]. Her-
pesviruses can reactivate in DIHS in a sequential order as
occurs in graft-versus-host disease [12,13].
How is HHV-6 acquired? HHV-6 infects nearly all
humans by age 2 years [14]. Most infections arise through
the exchange of infected saliva during the first years of
life, although perinatal transmission can also occur. It has
recently been shown that HHV-6 DNA can be chromoso-
mally integrated into host DNA, and chromosomally
integrated HHV-6 is thought to be the major mode of
congenital infection [15]. This has been demonstrated
also in the setting of DIHS [16].
It is well established that viral infections and drug
allergy are the defining features of DIHS; however, which
condition is the cause and which is the effect? The trigger
could be an allergic reaction to the causative drug that
stimulates T cells [17]. T-cell stimulation leads to reacti-
vation of the herpesvirus viral genome harbored in T
cells. This would explain the cascade of herpesvirus reac-
tivation in DIHS [12,13]. Alternatively, DIHS could be
triggered by herpesvirus reactivation, which is clinically
silent. Virus-stimulated T cells can cross-react with the
drug thereby leading to expansion of specific T cells. Sub-
sequently, HHV-6 can reactivate heterologous viruses as
has been demonstrated in vitro [18]. The temporal rela-
tionship between therapy onset and DIHS onset (from 3
weeks to 3 months) suggests that the virus does not play a
primary role in the syndrome. Therefore, we favor a pri-
mary allergic reaction pathogenesis.
Immunologically, patients with DIHS have decreased
total IgG, IgA and IgM levels and B-lymphocytes at dis-
ease onset [19,20], whereas there is an expansion of mem-
ory T cells that cross-react with both the drug and the
virus. It is noteworthy that lymphocyte transformation
test, which is used to diagnose drug-specific T-cell
responses in the clinical setting, is negative in the first
week after DIHS onset and continues to be negative in
90% of patients 2 weeks after disease onset [21]. The test
becomes positive 5-7 weeks after disease onset. These
results could be due to expansion of regulatory T cells
(that suppress proliferation of memory T cells) in the ini-
tial stages of the disease and their subsequent decrease
via apoptosis [21]. Several cytokines are increased during
DIHS. In particular, the levels of TNF-alpha and IL-6,
which are typical inflammatory cytokines, are elevated in
DIHS before HHV-6 infection [22]. Interestingly, IL-6
levels become undetectable during viral infection and
increase again after infection in most patients [22].
Clinical Features
The first symptom of DIHS is fever, which is often high
(38-40°C) and is followed by itchy, patchy erythematous
maculae (often with follicular accentuation) that can
become confluent. Rash starts on face, upper trunk and
upper extremities. In some cases, especially when the
causative drug is not discontinued, a severe exfoliative
dermatitis occurs. Tender lymphadenopathy (limited to
cervical nodes or generalized) is often present. Hepatic
involvement is common: hepatomegaly and splenomeg-
aly are often found at clinical examination. Bilateral swell-
ing of the salivary glands with xerostomia has been
frequently reported. A typical feature of DIHS is a para-
doxical worsening of symptoms after withdrawal of the
causative drug [21].
Laboratory data are helpful in diagnosing DIHS: leuko-
cytosis with eosinophilia and atypical lymphocyte count
increase are common findings. Both CD4 and CD8 cells
are increased in DIHS patients. Similarly, ALT levels are
increased in most patients, and hepatitis is often anict-
eric. Renal involvement is less common. It includes tubu-
lointerstitial nephritis and granulomatous necrotizing
angitis [21]. Serum IgG, IgA and IgM levels are often
decreased. Another important laboratory feature is the
presence of HHV-6 DNA (by PCR) and IgM against
HHV-6 in serum.
The death rate of DIHS is 20% [23] and it is associated
with older age, renal involvement, hepatitis with jaundice
and CMV reactivation. In contrast, EBV reactivation is
associated with a milder form of the disease. However, in
the latter cases there is a higher rate of development of
autoimmune diseases such as type 1 diabetes mellitus
[24] and autoimmune hypothyroidism [1]. These autoim-
mune diseases can occur even several years after resolu-
tion of the DIHS. Complications are rare; they include
limbic encephalitis, thyroid diseases, renal failure, syn-
drome of inappropriate secretion of antidiuretic hormone
[25], spleen rupture [26], eosinophilic colitis [27], eosino-
philic esophagitis [28], and myocarditis [29]. A recent
report has described a case of lethal enterocolitis associ-
ated with CMV reactivations in the setting of DIHS [30].
Diagnosis
Although the individual symptoms of DIHS are not spe-
cific and can suggest another disease (e.g. lymphoprolif-
erative disease, connectivitis, etc.), their combination
associated with HHV-6 infection and the concomitant
use of a drug can indicate the diagnosis. A Japanese group
has devised a list of criteria for a diagnosis of DIHS
[21,31]: 1. Maculopapular rash developing >3 weeks after
starting therapy with a limited number of drugs; 2. Pro-
longed clinical symptoms after discontinuation of the
causative drug; 3. Fever (>38°C); 4. Hepatitis (ALT >100
U/L) or renal involvement; 5. Leukocyte abnormalities (a.
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(>5%), c. Eosinophilia (1.5 × 109/L)); 6. Lymphadenopa-
thy; 7. HHV-6 reactivation. The presence of 7 criteria is
indicative of typical DIHS. The presence of 5 criteria is
indicative of atypical DIHS [21,31].
Reactivation of HHV-6 or other herpesviruses can be
assessed by PCR or specific IgM. However, as herpesvirus
infections associated with DIHS represent likely a reacti-
vations from latency, most patients would probably
express specific IgM over a relatively short time window
(since the secondary T helper cell response kicks in more
rapidly, driving a more rapid isotype conversion for newly
arisen circulating naïve B lymphocytes). Moreover it is
noteworthy that in the course of DIHS a dramatic
decrease in immunoglobulin production occurs [31].
Therefore PCR seems to be a more reliable marker for
current herpesvirus activity than specific IgM.
Therapy
DIHS is treated with oral corticosteroids (1-1.5 mg/kg
body weight/day). It is noteworthy that rapid tapering of
corticosteroids is associated with reactivation of the syn-
drome [32] as occurred in our patient. Intravenous IgG
and plasma exchange have been successful in cases in
which the disease did not regress under corticosteroids
[33]. Intravenous immune globulin may act by forming
immune complexes that block IgG Fc receptors, by neu-
tralizing autoantibodies, and by controlling virus infec-
tion.
In some case reports, N-acetylcysteine together with
immune globulin was successfully used [32].
Conclusions
The case reported herein demonstrates that comprehen-
sive medical history-taking and the search for rare causes
of fever can lead to complete resolution of a very difficult
case. The most relevant issue related to DIHS is its identi-
fication. Physicians should suspect it in all cases of fever
that appears several weeks after the administration of a
drug (usually an antiepileptic drug). Treatment is usually
successful once the condition has been diagnosed. A crit-
ical issue is the duration of treatment. What this case
clearly shows is that steroidal tapering should be very
slow. However no study has been carried out to assess the
ideal length of the treatment.
We underline that acyclovir, started as empirical treat-
ment due to worsening conditions of the patient, likely
had no role in the resolution of the symptoms. HHV-6
DNA was positive in the blood the day after acyclovir
withdrawn.
DIHS is a paradigmatic disease in which drugs and
infections interact with the immune system to generate a
syndrome constituted by a lymphoproliferative disease,
an autoimmune disease, an infectious disease and an
allergic reaction. The study of the pathogenesis of DIHS
could shed light on the pathogenesis of several other
immune diseases.
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